E-LIB Suche - Ergebnisse für: Al-Hashami, Zamzam

1

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥50% Treat..:

Rittberg, Rebekah ; Leung, Bonnie ; Shokoohi, Aria...
Current Oncology. 30 (2023) 6 - p. 5299-5308 , 2023

Link: https://doi.org/10.3390/..

2

Improved uptake and survival with systemic treatments for m..:

Leung, Bonnie ; Shokoohi, Aria ; Al-Hashami, Zamzam...
BMC Cancer. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

3

The Prevalence and Patterns of Toxicity With Immune Checkpo..:

Salman, Bushra ; AlWard, Nameer M ; Al-Hashami, Zamzam...
Cureus. , 2023

Link: https://doi.org/10.7759/..

4

Impact of Tumor Location on Patient Outcomes in Small Bowel..:

Yu, Irene S. ; Al-Hashami, Zamzam ; Chapani, Parv...
Clinical Colorectal Cancer. 21 (2022) 2 - p. 107-113 , 2022

Link: https://doi.org/10.1016/..

5

Real-world eligibility for platinum doublet plus immune che..:

Rittberg, Rebekah ; Leung, Bonnie ; Al-Hashami, Zamzam.
Frontiers in Oncology. 12 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

6

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC w..:

Jones, Lauren ; Rittberg, Rebekah ; Leung, Bonnie...
Current Oncology. 29 (2022) 11 - p. 8686-8692 , 2022

Link: https://doi.org/10.3390/..

7

Pulmonary Toxicities of Immune Check Point Inhibitors in th..:

Jayakrishnan, B ; Al-Moundhri, Mansour ; Burney, Ikram..
Advances in Respiratory Medicine. 90 (2022) 3 - p. 219-229 , 2022

Link: https://doi.org/10.5603/..

8

Real World Patient Eligibility for Second Line Lurbinectedi..:

Rittberg, Rebekah ; Leung, Bonnie ; Al-Hashami, Zamzam.
Current Oncology. 29 (2022) 12 - p. 9744-9752 , 2022

Link: https://doi.org/10.3390/..

9

Discordance in PD-L1 scores on repeat testing of non-small ..:

Naso, Julia R. ; Banyi, Norbert ; Al-Hashami, Zamzam...
Cancer Treatment and Research Communications. 27 (2021) - p. 100353 , 2021

Link: https://doi.org/10.1016/..

10

Hepatocellular Carcinoma in Oman: An analysis of 284 cases:

Al-Naamani, Khalid ; Al-Hashami, Zamzam ; Al-Siyabi, Omar...
Sultan Qaboos University Medical Journal [SQUMJ]. 20 (2020) 3 - p. 316 , 2020

Link: https://doi.org/10.18295..

11

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Trea..:

Rittberg, Rebekah ; Leung, Bonnie ; Shokoohi, Aria...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297524/. , 2023

Link: http://www.ncbi.nlm.nih...

12

Improved uptake and survival with systemic treatments for m..:

Leung, Bonnie ; Shokoohi, Aria ; Al-Hashami, Zamzam...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114445/. , 2023

Link: http://www.ncbi.nlm.nih...

13

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC w..:

Jones, Lauren ; Rittberg, Rebekah ; Leung, Bonnie...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689400/. , 2022

Link: http://www.ncbi.nlm.nih...

14

Real World Patient Eligibility for Second Line Lurbinectedi..:

Rittberg, Rebekah ; Leung, Bonnie ; Al-Hashami, Zamzam.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776936/. , 2022

Link: http://www.ncbi.nlm.nih...

15

Lung cancer screening in the gulf: Rationale and recommenda..:

Bennji, Sami M ; Jayakrishnan, B ; Al-Kindi, Adil H..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662086/. , 2022

Link: http://www.ncbi.nlm.nih...